Caco-2 cells permeability evaluation of nifuroxazide derivatives with potential activity against methicillin-resistant Staphylococcus aureus (MRSA)
Abstract Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to...
Saved in:
Published in: | Drug development and industrial pharmacy Vol. 41; no. 7; pp. 1066 - 1072 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
England
Informa Healthcare USA, Inc
01-07-2015
Informa Healthcare |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Abstract
Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to develop in vitro assays through Caco-2 cells in order to analyze the permeability of 5-nitro-heterocyclic compounds analogues to nifuroxazide with antimicrobial activity, especially showing promising activity against multidrug-resistant Staphylococcus aureus (MRSA). Caco-2 cell monolayers cultivated for 21 days in Transwell® plates were used for the in vitro permeability assays. The quantification of the nifuroxazide derivatives in the basolateral chambers was performed by a validated high performance liquid chromatography with UV (HPLC-UV) method. Apparent permeability values (Papp) show that these compounds can be considered as new drug candidates with the potential to present high absorption in vivo, according to the classifications of Yee and Biganzoli. The thiophenic derivatives showed permeability values higher than the furanic ones, being AminoTIO the compound with the greatest potential for the development of a new drug against MRSA, since it showed the best cytotoxicity, permeability and solubility ratio among all the derivatives. |
---|---|
AbstractList | Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to develop in vitro assays through Caco-2 cells in order to analyze the permeability of 5-nitro-heterocyclic compounds analogues to nifuroxazide with antimicrobial activity, especially showing promising activity against multidrug-resistant Staphylococcus aureus (MRSA). Caco-2 cell monolayers cultivated for 21 days in Transwell® plates were used for the in vitro permeability assays. The quantification of the nifuroxazide derivatives in the basolateral chambers was performed by a validated high performance liquid chromatography with UV (HPLC-UV) method. Apparent permeability values (Papp) show that these compounds can be considered as new drug candidates with the potential to present high absorption in vivo, according to the classifications of Yee and Biganzoli. The thiophenic derivatives showed permeability values higher than the furanic ones, being AminoTIO the compound with the greatest potential for the development of a new drug against MRSA, since it showed the best cytotoxicity, permeability and solubility ratio among all the derivatives. Abstract Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient refinement of the molecular structure has been widely appraised by the transport of substances across cell monolayers. This study aims to develop in vitro assays through Caco-2 cells in order to analyze the permeability of 5-nitro-heterocyclic compounds analogues to nifuroxazide with antimicrobial activity, especially showing promising activity against multidrug-resistant Staphylococcus aureus (MRSA). Caco-2 cell monolayers cultivated for 21 days in Transwell® plates were used for the in vitro permeability assays. The quantification of the nifuroxazide derivatives in the basolateral chambers was performed by a validated high performance liquid chromatography with UV (HPLC-UV) method. Apparent permeability values (Papp) show that these compounds can be considered as new drug candidates with the potential to present high absorption in vivo, according to the classifications of Yee and Biganzoli. The thiophenic derivatives showed permeability values higher than the furanic ones, being AminoTIO the compound with the greatest potential for the development of a new drug against MRSA, since it showed the best cytotoxicity, permeability and solubility ratio among all the derivatives. |
Author | Gonçalves, José E. C. Tavares, Leoberto Storpirtis, Sílvia B. Fernandes, Mariane |
Author_xml | – sequence: 1 givenname: Mariane surname: B. Fernandes fullname: B. Fernandes, Mariane email: mmarianebf@gmail.com, mmarianebf@gmail.com organization: Pharmacy Department, Pharmaceutical Sciences Faculty, University of São Paulo – sequence: 2 givenname: José E. surname: Gonçalves fullname: Gonçalves, José E. email: mmarianebf@gmail.com, mmarianebf@gmail.com organization: Pharmacy Department, Pharmaceutical Sciences Faculty, University of São Paulo – sequence: 3 givenname: Leoberto surname: C. Tavares fullname: C. Tavares, Leoberto email: mmarianebf@gmail.com, mmarianebf@gmail.com organization: Chemical and Pharmaceutical Technology Department, Pharmaceutical Sciences Faculty, University of São Paulo – sequence: 4 givenname: Sílvia surname: Storpirtis fullname: Storpirtis, Sílvia email: mmarianebf@gmail.com, mmarianebf@gmail.com organization: Pharmacy Department, Pharmaceutical Sciences Faculty, University of São Paulo |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24918173$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAUhS1URKeFN0DIy3aRwXbiJN6AqhF_UhEShXV047lmXDl2sJ0pw2vwwiSaFolNV1eyv3Pu1Tln5MQHj4S85GxdcqZes7IuFavkWjBerZWQiqsnZMWlYIVsanFCVgtSLMwpOUvpljEulJTPyKmoFG95U67Inw3oUAiq0blER4wDQm-dzQeKe3ATZBs8DYZ6a6YYfsFvu0W6xWj389ceE72zeUfHkNFnC46Cnp8XOfwA61OmA-ad1dY564uIyaYMPtObDOPu4IIOWk-JwhRxHhefv95cXT4nTw24hC_u5zn5_v7dt83H4vrLh0-bq-tCV7zNRVuLSoIUxqhW8FYiR63qtsW6EWWtVW-YMXMqvWgFa5q6lwb7ptkybkRf1VCek4uj7xjDzwlT7gabliDAY5hSx2vFpap4zWa0OqI6hpQimm6MdoB46Djrljq6hzq6pY7uWMcse3W_YeoH3P4TPeQ_A2-PgPUmxAHuQnTbLsOcTDQRvLZpsX90xZv_HHYILu80ROxuwxT9HODjN_4Fr3Sx3w |
CitedBy_id | crossref_primary_10_1016_j_molliq_2021_116911 crossref_primary_10_1002_slct_202305142 crossref_primary_10_1007_s10534_018_0160_0 crossref_primary_10_1016_j_drudis_2019_06_017 crossref_primary_10_1016_j_ejps_2019_105092 crossref_primary_10_1016_j_jddst_2019_101413 |
Cites_doi | 10.1002/bdd.2510070504 10.1016/S0928-0987(03)00146-5 10.1021/js9803205 10.3109/03639045.2012.746362 10.1023/A:1018961828510 10.1128/AAC.31.9.1429 10.1099/00222615-37-3-221 10.3109/03639045.2012.723218 10.1016/j.bmc.2009.03.011 10.1023/A:1020483911355 10.1007/978-1-4899-1863-5_3 10.1023/A:1012102522787 10.5694/j.1326-5377.2004.tb06444.x 10.1023/A:1018990602102 10.1016/S0014-827X(99)00069-5 10.1016/S0378-5173(98)00330-5 10.1016/j.bmc.2007.03.068 10.1023/A:1012155124489 10.1002/jps.20149 10.1016/j.mib.2004.08.007 10.1016/S0378-5173(00)00334-3 10.1016/S1056-8719(00)00113-1 10.1007/s11095-004-9004-4 10.1002/jps.2600790710 10.1208/s12248-010-9176-2 10.3109/03639045.2014.900077 10.1124/dmd.110.034629 10.1016/j.febslet.2007.05.051 10.1023/A:1018937416447 10.1016/S1359-6446(04)03354-9 10.1023/A:1007585105753 10.1016/j.tiv.2012.01.018 10.1016/0006-291X(91)91647-U |
ContentType | Journal Article |
Copyright | 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted 2014 |
Copyright_xml | – notice: 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted 2014 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.3109/03639045.2014.925919 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-5762 |
EndPage | 1072 |
ExternalDocumentID | 10_3109_03639045_2014_925919 24918173 925919 |
Genre | Research Articles Journal Article Comparative Study |
GroupedDBID | --- .GJ 00X 03L 0BK 0R~ 29G 36B 4.4 53G 5GY 5VS 8VB AACCU AAJNR AALIY AALUX AAMIU AAPUL AAPXX AAQRR ABBKH ABCRQ ABEIZ ABLKL ABUPF ACENM ACFUF ACGEJ ACGFS ACLSK ADCVX ADFCX ADRBQ ADXPE AECIN AEMOZ AENEX AEOZL AEYQI AFAUU AFKVX AFOSN AFQCT AFWLO AGAFX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJEBJ AJWEG AJXHO AKBVH AKVCP ALIIL ALMA_UNASSIGNED_HOLDINGS ALQZU AWYRJ BABNJ BLEHA BOHLJ BVLLS CAG CCCUG COF CS3 DEIEU DKSSO DLVIE DTRLO DU5 DZHFC EBC EBD EBO EBR EBS EBU EHE EJD EMB EMK EMOBN EPL F5P H13 HZ~ IPNFZ J.N JFOCU KRBQP KSSTO KUULJ KWAYT KYCEM LJTGL LSO M44 M4Z MK0 O9- QRXOQ QWB RNANH RVRKI SV3 TFDNU TFL TFW TH9 UHWXJ V1S Y6R ZL0 ~1N ABJNI ABLIJ ABXYU ACIEZ ALYBC CGR CUY CVF ECM EIF K1G NPM NUSFT TBQAZ TDBHL TERGH TUROJ AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c418t-86245a52ff982185e1ec9688e67236c9bf0ff591b2820776b5feb77d01f2b46a3 |
ISSN | 0363-9045 |
IngestDate | Fri Oct 25 22:35:02 EDT 2024 Thu Nov 21 22:58:09 EST 2024 Tue Oct 15 23:55:29 EDT 2024 Tue Jun 13 19:51:27 EDT 2023 Tue Jul 04 19:21:04 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | biopharmacy drug development 5-Nitro-heterocyclic intestinal absorption anti-infectives |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-86245a52ff982185e1ec9688e67236c9bf0ff591b2820776b5feb77d01f2b46a3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 24918173 |
PQID | 1691594160 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | crossref_primary_10_3109_03639045_2014_925919 informaworld_taylorfrancis_310_3109_03639045_2014_925919 proquest_miscellaneous_1691594160 pubmed_primary_24918173 informahealthcare_journals_10_3109_03639045_2014_925919 |
PublicationCentury | 2000 |
PublicationDate | 2015-07-01 |
PublicationDateYYYYMMDD | 2015-07-01 |
PublicationDate_xml | – month: 07 year: 2015 text: 2015-07-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Drug development and industrial pharmacy |
PublicationTitleAlternate | Drug Dev Ind Pharm |
PublicationYear | 2015 |
Publisher | Informa Healthcare USA, Inc Informa Healthcare |
Publisher_xml | – name: Informa Healthcare USA, Inc – name: Informa Healthcare |
References | CIT0030 Charles PGP (CIT0003) 2004; 181 CIT0010 CIT0032 CIT0031 CIT0012 CIT0034 CIT0011 CIT0033 Gonçalves JE (CIT0017) 2009 Shah RR (CIT0026) 1989; 8 Rubas W (CIT0015) 1995; 5 Buzard JA (CIT0025) 1961; 131 CIT0014 CIT0036 CIT0013 CIT0035 CIT0016 CIT0038 CIT0037 CIT0018 CIT0039 CIT0019 Ferraz HG (CIT0043) 2009 CIT0041 CIT0040 CIT0021 CIT0020 CIT0042 CIT0023 Nakao M (CIT0001) 2006; 12 CIT0002 CIT0024 CIT0005 CIT0027 CIT0004 CIT0007 CIT0006 CIT0028 CIT0009 CIT0008 |
References_xml | – ident: CIT0024 doi: 10.1002/bdd.2510070504 – ident: CIT0032 doi: 10.1016/S0928-0987(03)00146-5 – ident: CIT0010 doi: 10.1021/js9803205 – ident: CIT0042 doi: 10.3109/03639045.2012.746362 – ident: CIT0013 doi: 10.1023/A:1018961828510 – ident: CIT0020 doi: 10.1128/AAC.31.9.1429 – ident: CIT0021 doi: 10.1099/00222615-37-3-221 – ident: CIT0040 doi: 10.3109/03639045.2012.723218 – ident: CIT0004 doi: 10.1016/j.bmc.2009.03.011 – volume: 8 start-page: 183 year: 1989 ident: CIT0026 publication-title: Adverse Drug React Acute Poisoning Rev contributor: fullname: Shah RR – ident: CIT0036 doi: 10.1023/A:1020483911355 – volume: 5 start-page: 93 year: 1995 ident: CIT0015 publication-title: S.T.p. Pharma Sci contributor: fullname: Rubas W – ident: CIT0031 doi: 10.1007/978-1-4899-1863-5_3 – ident: CIT0018 doi: 10.1023/A:1012102522787 – volume: 181 start-page: 549 year: 2004 ident: CIT0003 publication-title: Med J Aust doi: 10.5694/j.1326-5377.2004.tb06444.x contributor: fullname: Charles PGP – ident: CIT0014 doi: 10.1023/A:1018990602102 – ident: CIT0019 doi: 10.1016/S0014-827X(99)00069-5 – ident: CIT0016 doi: 10.1016/S0378-5173(98)00330-5 – ident: CIT0023 – ident: CIT0005 doi: 10.1016/j.bmc.2007.03.068 – ident: CIT0007 doi: 10.1023/A:1012155124489 – ident: CIT0035 – ident: CIT0038 doi: 10.1002/jps.20149 – ident: CIT0002 doi: 10.1016/j.mib.2004.08.007 – ident: CIT0011 doi: 10.1016/S0378-5173(00)00334-3 – ident: CIT0006 doi: 10.1016/S1056-8719(00)00113-1 – ident: CIT0039 doi: 10.1007/s11095-004-9004-4 – ident: CIT0030 doi: 10.1002/jps.2600790710 – ident: CIT0037 doi: 10.1208/s12248-010-9176-2 – start-page: 204 volume-title: Biofarmacotécnica – série ciências farmacêuticas year: 2009 ident: CIT0017 contributor: fullname: Gonçalves JE – ident: CIT0041 doi: 10.3109/03639045.2014.900077 – volume: 12 start-page: 1 year: 2006 ident: CIT0001 publication-title: Kaw J Med Welfare contributor: fullname: Nakao M – ident: CIT0027 doi: 10.1124/dmd.110.034629 – ident: CIT0033 doi: 10.1016/j.febslet.2007.05.051 – ident: CIT0012 doi: 10.1023/A:1018937416447 – start-page: 66 volume-title: Biofarmacotécnica – série ciências farmacêuticas year: 2009 ident: CIT0043 contributor: fullname: Ferraz HG – ident: CIT0009 doi: 10.1016/S1359-6446(04)03354-9 – volume: 131 start-page: 38 year: 1961 ident: CIT0025 publication-title: J Pharmacol Exp Ther contributor: fullname: Buzard JA – ident: CIT0034 doi: 10.1023/A:1007585105753 – ident: CIT0028 doi: 10.1016/j.tiv.2012.01.018 – ident: CIT0008 doi: 10.1016/0006-291X(91)91647-U |
SSID | ssj0012955 |
Score | 2.184722 |
Snippet | Abstract
Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an... Throughout the period of evaluation and selection in drug development, the assessment of the permeability potential of a compound to achieve an efficient... |
SourceID | proquest crossref pubmed informaworld informahealthcare |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1066 |
SubjectTerms | 5-Nitro-heterocyclic Anti-Infective Agents - administration & dosage Anti-Infective Agents - pharmacokinetics Anti-Infective Agents - pharmacology anti-infectives biopharmacy Caco-2 Cells Chromatography, High Pressure Liquid drug development Humans Hydroxybenzoates - administration & dosage Hydroxybenzoates - pharmacokinetics Hydroxybenzoates - pharmacology intestinal absorption Methicillin-Resistant Staphylococcus aureus - drug effects Nitrofurans - administration & dosage Nitrofurans - pharmacokinetics Nitrofurans - pharmacology Permeability Solubility Spectrophotometry, Ultraviolet |
Title | Caco-2 cells permeability evaluation of nifuroxazide derivatives with potential activity against methicillin-resistant Staphylococcus aureus (MRSA) |
URI | https://www.tandfonline.com/doi/abs/10.3109/03639045.2014.925919 https://www.ncbi.nlm.nih.gov/pubmed/24918173 https://search.proquest.com/docview/1691594160 |
Volume | 41 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3JbtswECXi5NJLke7uBhYoghaOXJvaj4btNpcEQeMCvQmURKYCUsuQJaPpb_SHO0NSi1N3BXoRDBk0Zb3H4cxwFkJewh6fusJOLd-LheWAxm3xQKYWC9LQEyxxY9UO6OTCP_sYzObOfK9Xt7ds7_1XpOEeYI2Zs3-BdvOjcAM-A-ZwBdTh-ke4T0HEWWyADvk1FiX-LHQl7utOYW8VvZHJqsi_8K9ZiqlThepyhiVolWd2lZcYRoSFBBLTX4Jf8gx0SdVzOkvQTbO0wFZH_XNZotIKgMHOmCdJtR7wqhCVcuievr-Y1O4GowTPiuqyztZqYtyztofISpfTblMthoPa3b02-UVA6oaR70B7xeN-n19tRH2soQMABvNhc8gyHCz4BrOtlCtCqIjyvHEwlXmxyrAztXIHq9Gzq03Gu16RsdtE0BpLeSuXC4PoOnIVj67Dka5iORRG7oMV7d7YGHRFLrMA_I6UBzPa62gMYEGzXbuRrYu54nw4HcYROsMQ7E2zSWzX-dZf9MgBA5EJEvtgMp2fnTYnYixUHXybh9dpoDjFm10TbKlZh6YI76fmbdwozPtz80qpWYtDctvYR3SiiX2H7InlXXJ0bhhxTBdtvuD6mB7R87b0-vU98k2znyr20y77act-mkvaZT_tsJ8i-2nDflqznxr2053sp9vsp5r99BVy__V98uHtfDE9sUzbEStxxkFpYcqUy10mZRiAAuyKsUhCLwiE5zPbS8JYjqSEdxwz0J59kHGuFLHvp6OxZLHjcfsB2V_mS_GIUDCn7GTEQCWXgZPYNg-8kNuB5_joR-Bxn1g1StFKV5eJwCpHVKMa1QhRjTSqfeL_AGVkhM_6NyODLuBRqfyBUjfvwWG_GvqiJkcEew8iCGs8r2BCLwRrCMT9qE8eatY0f4M5IRgPvv343yd-Qm61S_sp2S-LSjwjvXVaPTer4zsLJQYP |
link.rule.ids | 315,782,786,27933,27934,59868,60657,61275,61456 |
linkProvider | Taylor & Francis |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELage4DLsrzL00hoBdJ6N83DsY9V6aqIbbVii8TNchwbekmqJllR_gZ_mJk4bXloQUKcEilyHGdm7G_smW8IeQlrfJ7YKGcpzyyLAXEzLVzOQpFLbkOTZG05oMlFOvso3oyRJme4yYXBsEr0oZ0nimjnajRu3Iw-aV3MQJ7g4aMELIKRWfGxBASPxJ97SDUuemRvOBrPptujhFC2pU_bA0ts5PPnrnzPT-vTQcde-nkbi_ULo-nVuLRdn05v_YeRHZD9DpzSodem2-SaLe6Qw3PPbr0-ovNdslZ1RA_p-Y73en2XfBvBLQspngVUdAlTvvUk4Gu64xSnpaPFwjWr8ov-usgtzcEELlv28YripjBdljVGMMF3YM4Flrag-pNeAIylWO56YXCHqGArWyH0LWoKeBl0BRbl0pimorpZWbi8mr6_GL6-Rz6cjuejCetqPjATD0TNMF8l0UnonBSAPhI7sEZyISxPw4gbmbnAOfgrGbiKyESUJc5maZoHAxdmMdfRfdIrysI-JBSwbGSCEPCQE7GJIi241JHgcYpOnM76hG0krZae2kOBS4RyUBs5KJSD8nLok_Q3dVCdxVd_aSl-VBpVt5sxzldOwWZ_avpio2AKDB8lqAtbNtAhlwBFwdaCPnngNW87DPCpAbml0aN_7_g5uTGZT8_U2dvZu8fkJjxJfJTyE9KrV419Sq5XefOss7bvvugnbQ |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdgkxAvY3wXGBgJTSDNW5oPx36sulZDsKpiQ-ItcvwBfUmqJpnW_Rv8w9zFaTtAAwmeEilyHOfu7N_Zd78j5A2s8SaxkWEpzy2LAXEzJZxhoTCS21AneVsO6OQsnXwRxyOkyVln8WNYJfrQzhNFtHM1GvfcuKPWwwzkEZ49SoAiGJgVH0oA8Mj7uQ1QPAH3a3swHE1O1ycJoWwrn7bnldjIp8_d-J6flqfdjrz02zoU6xdC05thabs8je_9_8B2yU4HTenA69J9cssWD8j-1HNbLw_o-SZVqzqg-3S6Yb1ePiTfh3DLQoonARWdw4RvPQX4km4YxWnpaDFzzaK8VFczY6kBA7houccrilvCdF7WGL8E34EZF1jYgqqvagYglmKx65nG_aGCLWyFwLeoKaBl0BRYkkutm4qqZmHh8vb009ng3SPyeTw6H56wruID03Ff1AyzVRKVhM5JAdgjsX2rJRfC8jSMuJa5C5yDv5KDo4g8RHnibJ6mJui7MI-5ih6TraIs7FNCAclGOggBDTkR6yhSgksVCR6n6MKpvEfYStDZ3BN7ZOAQoRyylRwylEPm5dAj6W_akHX2Xv2lpbiuM1ndbsU4XzcFm_2p6euVfmVg9ihBVdiygQ65BCAKlhb0yBOveOthgEcNuC2Nnv17x6_InenxOPv4fvLhObkLDxIfovyCbNWLxu6R25VpXna29gP1UiYR |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Caco-2+cells+permeability+evaluation+of+nifuroxazide+derivatives+with+potential+activity+against+methicillin-resistant+Staphylococcus+aureus+%28MRSA%29&rft.jtitle=Drug+development+and+industrial+pharmacy&rft.au=B.+Fernandes%2C+Mariane&rft.au=Gon%C3%A7alves%2C+Jos%C3%A9+E.&rft.au=C.+Tavares%2C+Leoberto&rft.au=Storpirtis%2C+S%C3%ADlvia&rft.date=2015-07-01&rft.pub=Informa+Healthcare&rft.issn=0363-9045&rft.eissn=1520-5762&rft.volume=41&rft.issue=7&rft.spage=1066&rft.epage=1072&rft_id=info:doi/10.3109%2F03639045.2014.925919&rft.externalDocID=925919 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-9045&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-9045&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-9045&client=summon |